Literature DB >> 25314963

Timing (and biology) are everything.

Howard A Fine1.   

Abstract

Mesh：

Year:  2014        PMID： 25314963      PMCID： PMC4201078          DOI： 10.1093/neuonc/nou285

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  13 in total

1.  Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.

Authors:  Rifaquat Rahman; Kelly Hempfling; Andrew D Norden; David A Reardon; Lakshmi Nayak; Mikael L Rinne; Rameen Beroukhim; Lisa Doherty; Sandra Ruland; Arun Rai; Jennifer Rifenburg; Debra LaFrankie; Brian M Alexander; Raymond Y Huang; Patrick Y Wen; Eudocia Q Lee
Journal:  Neuro Oncol       Date:  2014-06-23       Impact factor: 12.300

2.  A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.

Authors:  Michael D Prados; S Clifford Schold; Howard A Fine; Kurt Jaeckle; Fred Hochberg; Laszlo Mechtler; Michael R Fetell; Surasak Phuphanich; Lynn Feun; Todd J Janus; Kathleen Ford; William Graney
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

3.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

Authors:  Kan V Lu; Jeffrey P Chang; Christine A Parachoniak; Melissa M Pandika; Manish K Aghi; David Meyronet; Nadezda Isachenko; Shaun D Fouse; Joanna J Phillips; David A Cheresh; Morag Park; Gabriele Bergers
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

4.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

Authors:  Michael D Prados; Kathleen Lamborn; W K A Yung; Kurt Jaeckle; H Ian Robins; Minesh Mehta; Howard A Fine; Patrick Y Wen; Timothy Cloughesy; Susan Chang; M Kelly Nicholas; David Schiff; Harry Greenberg; Larry Junck; Karen Fink; Ken Hess; John Kuhn
Journal:  Neuro Oncol       Date:  2006-03-13       Impact factor: 12.300

6.  Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.

Authors:  A Soeda; M Park; D Lee; A Mintz; A Androutsellis-Theotokis; R D McKay; J Engh; T Iwama; T Kunisada; A B Kassam; I F Pollack; D M Park
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

7.  Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Authors:  Tracy T Batchelor; Mark R Gilbert; Jeffrey G Supko; Kathryn A Carson; Louis B Nabors; Stuart A Grossman; Glenn J Lesser; Tom Mikkelsen; Surasak Phuphanich
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

8.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

9.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.

Authors:  John F de Groot; Gregory Fuller; Ashok J Kumar; Yuji Piao; Karina Eterovic; Yongjie Ji; Charles A Conrad
Journal:  Neuro Oncol       Date:  2010-01-06       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.